Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices related to the company's clinical trial results and stock price decline [1]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Mereo and certain officers/directors engaged in securities fraud or other unlawful business practices [1]. - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to request to be appointed as Lead Plaintiff [1]. Group 2: Clinical Trial Results - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced that the Phase 3 Orbit study was progressing toward a final analysis, which led to a 42.52% drop in Mereo's ADR price, closing at $1.69 per share on July 10, 2025 [1]. - On December 29, 2025, Mereo announced that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in an 87.7% decline in ADR price, closing at $0.29 per ADR [1].

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Picard Medical, Inc. ("Picard" or the "Company") (NYSE: PMI). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 798 ...

Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of Rambus Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] Financial Performance - On February 2, 2026, Rambus reported its fourth quarter and fiscal year 2025 financial results [1] - The CFO indicated a one-time supply chain disruption is expected to impact product revenue by "probably around low double-digit million" for the first quarter of 2026 [1] Stock Market Reaction - Following the announcement of the supply chain disruption, Rambus's stock price fell by $15.26 per share, or 13.42%, closing at $98.45 per share on February 3, 2026 [1]

Core Viewpoint - A class action lawsuit has been filed against PomDoctor Ltd. for alleged securities fraud and unlawful business practices, with a significant drop in share price following a promotional scheme [1] Group 1: Class Action Lawsuit Details - The lawsuit is focused on whether PomDoctor and its officers engaged in securities fraud [1] - Investors have until April 6, 2026, to apply as Lead Plaintiff if they purchased PomDoctor securities during the Class Period [1] Group 2: Share Price Movement - PomDoctor's share price increased from $4.00 to an all-time high of $6.09 before crashing by approximately 91% to $0.50 on December 10, 2025 [1] - The price surge occurred without any fundamental news from the company, raising concerns about the legitimacy of the increase [1] Group 3: Allegations of Fraud - Investigations revealed that PomDoctor allegedly used social media for a "pump and dump" scheme, misleading investors through impersonation and baseless claims [1] - The promotional activities created a buying frenzy among retail investors, leading to significant financial losses [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in China Liberal Education Holdings Limited of Class Action Lawsuit and Upcoming Deadlines - CLEUF [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against China Liberal Education Holdings Limited ("CLEU" or the "Company") (OTCMKTS: CLEUF). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581 ...

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of Commvault Systems, Inc. following a significant decline in stock price after the company reported its third-quarter financial results for fiscal 2026 [1] Financial Performance - Commvault reported a 40% growth in SaaS ARR, reaching $364 million for the third quarter of fiscal 2026, which is a deceleration from the 56% growth reported in the second quarter of fiscal 2026 [1] - The company indicated that 60% of its deals closed in the last few weeks of the quarter [1] Stock Market Reaction - Following the financial results announcement, Commvault's stock price fell by $40.23 per share, approximately 31.1%, from a closing price of $129.36 on January 26, 2026, to $89.13 on January 27, 2026 [1]

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging that the company made materially false and misleading statements regarding its drug AMT-130 and its regulatory approval process [1][2]. Group 1: Lawsuit Details - The lawsuit is titled Scocco v. uniQure N.V., filed in the U.S. District Court for the Southern District of New York [1]. - Investors can move to serve as lead plaintiff by April 13, 2026, and the firm encourages those affected to contact them for more information [2]. Group 2: Company Background - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease (HD) [1]. - The leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal genetic disorder with no current cure [1]. Group 3: Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130 in March 2022 [1]. - The FDA had previously agreed that the Pivotal Study results could be compared to an external historical dataset (Enroll-HD) for the basis of a Biologics License Application (BLA) submission [1]. Group 4: Stock Performance and Offering - Following the announcement of positive topline results from the Pivotal Study on September 24, 2025, uniQure's stock price surged nearly 250%, from $13.66 to $47.50 per share [1]. - The company subsequently offered over 5.7 million shares and generated approximately $345 million in proceeds, despite uncertainties regarding AMT-130's future [2]. Group 5: Allegations of Misrepresentation - The complaint alleges that uniQure misrepresented the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline [2]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the Pivotal Study data would suffice for a BLA submission, leading to a stock price drop of over 49% [2].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. (NYSE: BRBR) for investors who acquired securities during the specified class period, highlighting significant stock price drops due to negative financial disclosures [1] Company Overview - BellRing Brands, Inc. is headquartered in St. Louis, MO, and specializes in marketing nutrition products, including ready-to-drink protein shakes, nutrition drinks, powders, and protein bars under the Premier Protein and Dymatize brands [1] Financial Performance - On May 6, 2025, BellRing's CFO indicated that several key retailers reduced their weeks of supply, which is expected to negatively impact third-quarter growth by a mid-single-digit percentage [1] - Following this announcement, BellRing's stock price fell by $14.88 per share, or 19%, from $78.43 on May 5, 2025, to $63.55 on May 6, 2025 [1] - On August 4, 2025, BellRing narrowed its fiscal year 2025 outlook for net sales, attributing the adjustment to competitors gaining market share with a large retailer, leading to a stock price drop of $17.46 per share, or 33%, from $53.64 on August 4, 2025, to $36.18 on August 5, 2025 [1]

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against PennyMac Financial Services, Inc. (PFSI) for possible violations of securities laws, particularly regarding misleading statements and undisclosed information [1] Financial Performance - PennyMac reported a pretax income of $37.3 million for its servicing segment in Q4 2025, a significant decrease from $157.4 million in the previous quarter and $87.3 million in Q4 2024 [1] - The company's retax income, excluding valuation-related items, was $47.8 million, reflecting a 70% decline from the prior quarter, primarily due to increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates led to higher prepayment activity [1] Market Reaction - Following the announcement of its financial results, PennyMac's shares experienced a sharp decline of 33.3% the next day [1]

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is recognized as one of the best revenue growth stocks, with a focus on developing therapies for rare genetic diseases, particularly through its resubmission of the Biologics License Application for UX111 AAV9 gene therapy targeting Sanfilippo syndrome type A [1][3]. Group 1: Company Developments - The company resubmitted its Biologics License Application (BLA) to the U.S. FDA on January 30, seeking accelerated approval for UX111 AAV9 gene therapy [1]. - The resubmitted BLA addresses previous concerns from the FDA, with an anticipated review period of up to six months, expected to conclude in the third quarter [3]. - If approved, UX111 will be the first therapy available for Sanfilippo syndrome type A [3]. Group 2: Analyst Ratings and Market Position - Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx Pharmaceutical with a price target of $50 [3]. - In the past month, Leerink Partners also issued a Buy rating, while Wedbush reiterated a Hold rating on the stock [3]. - The company’s product portfolio includes therapies such as Crysvita, Mepsevii, Dojolvi, and Evkeeza, emphasizing its commitment to rare and ultra-rare genetic diseases [3].